## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Please type a plus sign (+) inside this box → [+]  APR 1 5 2005  Under the Paperwork Reduction Act of 1995, no person are required to response	to a collection of information unless	PTO/SB08A (08-03)  Office; U. S. DEPARTMENT OF COMMERCE  s it contains a valid OMB control number
Substitute for form 1449A/PTO	COMPL	ETE IF KNOWN
Substitute for form 1449A/PTO	Application Number	10/662,644
INFORMATION DISCLOSURE	Confirmation Number	9385
STATEMENT BY APPLICANT	Filing Date	September 15, 2003
(use as many sheets as necessary)	First Named Inventor	Haught et al.
•	Group Art Unit	1616
•	Examiner Name	Not Yet Assigned
SHEET 1 of 4	Attorney Docket Number	8170XR

## **U. S. PATENT DOCUMENTS**

EXAMINER INITIALS	Cits No.1	DOCUMENT NUMBER	Publication Date MM-DD-YYYY	Name of Patentse or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
<b>∧</b> . ✓		Number - Kind Code <sup>2</sup> (If known)	09/29/1959	Stecker et al.	riguies Appear
HwY_	-	US-2,906,711	070/6/1976	Schenkel et al.	
	2	US-3,968,210	11/02/1976	Apostolatos et al.	<del></del>
	3	US-3,989,827	12/06/1977	Rubinfeld et al.	
	4	US-4,061,603	06/26/1962	Stecker et al.	
	5	US-3,041,236		Klausner et al.	
<u> </u>	6	US-3,666,668	05/30/1972		
	7	US-5,919,152	07/06/1999	Zygmont et al.	
	8	US-6,017,871	07/25/2000	Baeck et al.	
	9	US-4,287,191	09/01/1981	Cobum et al.	
	10	US-4,358,443	11/09/1982	Coburn et al.	
	11	US-5,958,911	09/28/1999	Evans et al.	
	12	US-6,117,859	9/12/2000	Evans et al.	<del></del>
	13	US-4,560,549	12/24/1985	Ritchey et al.	<del></del>
	14	US-4,647,452	030/3/1987	Ritchey et al.	
	15	US-4,742,083	05/3/1988	Ritchey et al.	
	16	US-4,725,590	02/16/1988	Ritchey et al.	
	17	US-4,939,132 equivalent to EP 0 198 366	07/03/1990	Coburn et al.	
	18	US-4,560,549 equivalent to EP 0 221 211	12/24/1985	Ritchey	
	19	US-4,287,191 equivalent to EP 0 038 191	09/01/1981	Coburn et al.	
	20	US-4,358,443 equivalent to EP 0 038 192	110/9/1982	Coburn et al.	
	21	US-3,311,562 equivalent to GB 1,088,498	03/28/1987	Stecker	
	22	US-3,666,808 equivalent to	05/30/1972	Meek	
	22	GB 1,254,999	-05/23/1967	Harich	<del></del>
	23	US-3,312,524 US-2002/0068014 A1	06/06/2002	Haught et al.	<del></del>
	24			Bogin	<del></del>
	25	US-2,092,300 A	09/07/1937	William	
	26	US-3,256,200 A	06/14/1966		
	27	US-3,594,322 A	07/20/1971	Wilson	
	28	US-3,664,961	05/23/1072		
	29	US-3,666,668	05/30/1972	Sawatari Kenichi etal.	
	30	US-4,008,274 A	02/15/1977	<u> برای می این این این این این این این این این ای</u>	
·	31	US-5,342,437 A	08/30/1994	Gavin	
	32	US-5,576,282	11/19/1996	Miracle et al.	<del></del>
	33	US-5,605,832	02/25/1997	Damhus et al. MacBeath	
	34	US-5,646,101	07/08/1997	Dallmier et al.	
	35	US-5,683,654	11/04/1997	Baillely et al.	1
	36	US-5,686,014	11/11/1997	روسها <del>در برای برای برای برای برای برای برای برا</del>	
	37	US-5,695,679	12/09/1997	Christie et al	
	38	US-5,698,504	12/16/1997	Christie et al.	<del></del>
	39	US-5,705,464	01/06/1998	Scheper et al.	<del> </del>
	40	US-5,707,950	01/13/1998	Kasturi etal.	<del></del>
-	41	US-5,710,115	01/20/1998	Patel et al.	·

•	43	US-6,159,720 equivalent of	12/12/2000	Murashima et al.	
		WO 98/03640 A			

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIALS*	Citie No.1		Code <sup>8</sup> Publ	ication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passeges or Relevant Figures Appear	7*
my	44	WO 02/28819 A1	04/11/	2002	The Research Foundation of State Univ. of New York	·	
-	45	WO 01/60157 A2	08/23/	2001	Procter & Gamble		
1.	46	WO 98/24800 A2	06/11/		Magainin Pharmaceuticals		
<del>-  </del>	47	WO 98/39403 A1	09/11/	1998	Procter & Gamble		
	48	WO 98/06808 A1	02/19/	البراي التناكر المناكر المساور المناسب	Procter & Gamble		
_	49	WO 98/06805 A1	02/19/	1998	Procter & Gamble		
	50	WO 98/06807 A1	02/19/	1998	Procter & Gamble		
	51	WO 98/39404 A1	09/11/	1998	Procter & Gamble		
_	52	WO 98/39402 A1	09/11/	1998	Procter & Gamble		
1	53	WO 98/16604 A2	04/23/	1998	Procter & Gamble		
	54	WO 98/40473 A1	09/17/	1998	Procter& Gamble		
	55	WO 96/16153 A1	05/30/	1996	Procter & Gamble		<u> </u>
	56	WO 98/12004 A1	04/25/	1996`	Procter & Gamble		<u> </u>
	57	WO 96/16154 A1	05/30/	/1996	Procter & Gamble	<u> </u>	<u> </u>
	58	WO 96/27649 A1	09/12/		Procter & Gamble	ļ	₩-
	59	WO 98/15633 A1	04/16/		Emalfarb	<u> </u>	
	60	WO 98/06809 A1	02/19/		Procter & Gamble		<del> </del>
	61	WO 98/13457 A1	04/02/		Procter & Gamble		├
	62	WO 96/28558 A1	09/19/		Procter & Gamble		<del> </del>
	63	WO 98/28394 A1	07/02		Procter & Gamble	·	<del> </del>
	64	WO 97/09431 A1	03/13/	/1997 	Novo Nordisk Biotech Inc. et al.	·	
	65	WO 97/31090 A1	08/28	/1997	Procter & Gamble		<b></b> _
	66	WO 97/11164 A1	03/27/		Genencor Int I. Inc.		ļ
	67	WO 99/09128 A1	02/25		Procter & Gamble		ļ
	68	WO 98/50513 A1	11/12		Procter & Gamble		ļ
	69	WO 99/02663 A1	01/21/		Novo Nordisk A/S		<del> </del>
	70	WO 98/38287 A1	09/03		Novo Nordisk A/S		<del> </del>
	71	WO 98/38286 A1	09/03		Novo Nordisk A/S	<u> </u>	┼─
	72	WO 98/27197 A1	06/25		Novo Nordisk A/S	<del></del>	<del> </del>
	73	WO 98/10060 A1	03/12		Novo Nordisk A/S Novo Nordisk A/S		┼
	74	WO 98/27198 A1	06/25		Novo Nordisk A/S		<del>                                     </del>
	75	WO 97/11217 A1	03/27		Novo Nordisk A/S		-
	76	WO 97/25468 A1	07/17		Novo Nordisk A/S	<u> </u>	<del> </del>
<del></del>	77	WO 97/25469 A1	10/30		Novo Nordisk A/S	1	┿
	78	WO 97/40127 A1	10/30		Novo Nordisk A/S	<del></del>	<del> </del>
	79	WO 97/40229 A1 WO 97/08325 A1	03/06		Novo Nordisk Biotech Inc. et		┼─
	80	WO 97/00325 A1	03/04	11001	al.		1
	81	WO 97/28257 A1	08/07	/1997	Novo Nordisk A/S		1
	82	WO 98/07816 A1	02/26	/1998	Procter & Gamble		
	83	WO 95/26397 A1	10/05	/1995	Novo Nordisk A/S		
	84	WO 96/23873 A1	08/08	/1996	Novo Nordisk A/S		
	85	WO 95/35382 A2		/1995	Gistbrocades B.V.		1
	86	EP 0 747469 A1		/1996	Procter & Gamble		—
	87	EP 0 709 452 A1	سنوبث بالأخارث أستساء بسيارك	/1996	Procter & Gamble	<u> </u>	<b>↓</b>
	88	E 0 747 470 A1		/1996	Procter & Gamble		<del> </del>
	89	EP 0 698 659 A1		/1996	Procter & Gamble		-
	90	GB 848,306		/1960	Colgate-Palmolive	<del> </del>	+
	91	GB 2 297 979 A		/1986	Procter & Gamble		+
	92	GB 2 294 269 A		/1996	Procter & Gamble	<del> </del>	<del></del>
	93	GB 2 303 147 A		/1997	Procter & Gamble		X
	94	JP 57-142,903		/1982 /1998	Dainippon Ink & Chemical Funayama et al.		<del> </del>
	95	JP 10088485 A JP 10174583 A		/1998 /1998	Echigo et al.		+÷
	96	JP 09316490 A		/1998	Suzuki et al.		<del> </del>
	98	JP 10088472 A		/1998	Matsuyama et al.		<del>  x</del>
	99	CH 500 861		/1988 /1971	Ciba-Gelgy	<del></del>	<del> </del>

and	100	BE 528,076 equivalent of FR 528,076	01/18/1957	Ciba Societe Anonyme	×
0. 1	101	FR 1,071,945	09/07/1954	CIBA	X
	102		05/24/1973	Henkel & Cie GmbH.	X
	103	DE 4428380 A1	2/15/1996	Bayer	X
	104	DE 195 23389 A1	01/09/1997	Bayer AG	X
	105	DE 196 12193 A1	10/02/1997	Consortium for the Electrochemical Industry GmbH	×
	106	CH 449,571 equivalent of 2071/65	09/15/1967	Stecker International	X
OM	107	FR 500,661		CIBA Geigy	
EXAMINE		Alpa Vygo		DATE CONSIDERED 9/1/05	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kind Codes of U.S. Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>5</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 37 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the Individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO-SB08
(Reyised for P&G use 10/8/2003)

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO	COMPLETE IF KNOWN		
	Application Number	10/662,644	
INFORMATION DISCLOSURE	Confirmation Number	9385	
STATEMENT BY APPLICANT	Filing Date	September 15, 2003	
(use as many sheets as necessary)	First Named Inventor	Haught et al.	
	Group Art Unit	1616	
•	Examiner Name	TBD	
SHEET 4 of 4	Attorney Docket Number	8170XR	

## NON PATENT LITERATURE DOCUMENTS

EXAMINER INITIALS	Cita No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			
AWY	108	NATARAJAN ET AL., 1992, Indian Drugs 29:545-552			
	109	LEMAIR ET AL., 1961 J. Pharmaceutical Sciences, 50:831-837			
	110				
	111	Abstract XP 002177846 equivalent to abstract for cite 117	<b> </b>		
	112	SMITH ET AL. Fungitoxic derivatives of salicyladehyde, 1961, Ann. Appl. Biol. Vol. 49, ppl 102-9			
	113	accession no 5293a XP002191164 & Chemical Abstracts, vol. 64, no. 4, February 14, 1966			
	114	from STN Database accession no. 71:51292 XP002191175 abstract & J. Oil Colour Chem. Ass. (1969), 52(7)			
	115	Medicinal Chemistry, Vol. 28, 1985, pages 143-146			
	116	J. H. AMIN, "The Fries Reaction, part IV-The Rearrangement of the Derivatives of Salicylic Acid & Substituted Benzoic Acids, Scientific & Industrial Research, Vol. 138, No. 1, 1954, pages 178-179			
Onl	117	TRUONG, PHUONG ET AL. "Synthesis and biological properties of chorosalicylamide derivatives" retrieved from STN Database accession no. 129:230511 XP 002191176 abstract & TAP CHI DUOC HOC (1998) (5) 8-12			
EXAMINE	AX	Ham My			

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

'Applicant's unique citation designation number (optional). 'Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 37 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO-SB08 (Revised for P&G use 10/8/2003)